Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | HTR1A | P08908 | 14/20 | 0.48 |
| ▸ | HTR1D | P28221 | 14/20 | 0.48 |
| ▸ | HTR1B | P28222 | 12/20 | 0.48 |
| ▸ | NCF1 | P14598 | 2/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.47 |
| ▸ | KHK | P50053 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2881010 | 1.00 | CYP2C9 (0.50) | CYP2C9HTR1AHTR1DHTR1BNCF1 | |
| SCHEMBL4180251 | 1.00 | CYP2C9 (0.50) | CYP2C9HTR1AHTR1DHTR1BNCF1 | |
| SCHEMBL3137750 | 0.85 | CYP2C9 (0.50) | CYP2C9HTR1AHTR1DHTR1BNCF1 | |
| SCHEMBL4175589 | 0.82 | PIM2 (0.41) | HTR1AHTR1DHTR1BNCF1ADRB2 | |
| SCHEMBL428165 | 0.82 | NCF1 (0.69) | CYP2C9HTR1AHTR1DHTR1BNCF1 | |
| SCHEMBL432590 | 0.81 | HTR1A (0.48) | HTR1AHTR1DHTR1BNCF1ADRB2 | |
| SCHEMBL14230828 | 0.81 | HTR1A (0.48) | HTR1AHTR1DHTR1BNCF1ADRB2 | |
| SCHEMBL3143283 | 0.81 | HTR1A (0.48) | HTR1AHTR1DHTR1BNCF1ADRB2 | |
| SCHEMBL13525153 | 0.79 | HTR1A (0.57) | CYP2C9HTR1AHTR1DHTR1BSLC6A4 | |
| SCHEMBL13525139 | 0.79 | HTR1A (0.57) | CYP2C9HTR1AHTR1DHTR1BSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| US-20100204273-A1 | Quinoline and Quinazoline Derivatives Having Affinity for 5HT1-Type Receptors | GLAXO GROUP LIMITED | 2010-08-12 | — | — | US | disclosed |
| US-7732600-B2 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| EP-2145622-A1 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | Glaxo Group Limited (GB) | 2010-01-20 | — | — | EP | disclosed |
| US-20100004452-A1 | 5-QUINOLINONE DERIVATIVES AS 5HT1A RECEPTOR MODULATORS FOR TREATING SEXUAL DYSFUNCTION, COGNITION IMPAIRMENT, PSYCHOTIC DISORDERS, ANXIETY, DEPRESSION, ETC. | GLAXO GROUP LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
| US-20090312546-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED | 2009-12-17 | — | — | US | disclosed |
| EP-1876174-B1 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LTD (GB) | 2009-11-11 | — | — | EP | disclosed |
| US-7592346-B2 | e.g. 3-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-1,3-oxazolidin-2-one; serotonin receptor antagonist and inverse agonists, agonists or partial agonists, serotonin reuptake inhibitor; antidepressant, anxiolytic agent | GLAXO GROUP LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| EP-2094686-A1 | 5-{2-[4-(2-METHYL-5-QUINOLINYL)-L-PIPERIDINYL]ETHYL} QUINOLINONE DERIVATIVES AS 5HT1A RECEPTOR MODULATORS FOR TREATING SEXUAL DYSFUNCTION, COGNITION IMPAIREMENT, PSYCHOTIC DISORDERS, ANXIETY, DEPRESSION, ETC. | Glaxo Group Limited (GB) | 2009-09-02 | — | — | EP | disclosed |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED | 2009-03-19 | — | — | US | disclosed |
| WO-2008037681-A1 | 5-{2-[4-(2-METHYL-5-QUINOLINYL)-L-PIPERIDINYL] ETHYL} QUINOLINONE DERIVATIVES AS 5HT1A RECEPTOR MODULATORS FOR TREATING SEXUAL DYSFUNCTION, COGNITION IMPAIREMENT, PSYCHOTIC DISORDERS, ANXIETY, DEPRESSION, ETC. | GLAXO GROUP LIMITED (GB) | 2008-04-03 | — | — | WO | disclosed |
| EP-1876174-A1 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LIMITED (GB) | 2008-01-09 | — | — | EP | disclosed |
| US-7279481-B2 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| US-20070167423-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED | 2007-07-19 | — | — | US | disclosed |
| EP-1786822-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-05-23 | — | — | EP | disclosed |
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | GLAXO GROUP LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| US-20060229312-A1 | Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors | GLAXO GROUP LIMITED (GB) | 2006-10-12 | — | — | US | disclosed |
| WO-2006024517-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
| EP-1562917-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004046124-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204273-A1 | Quinoline and Quinazoline Derivatives Having Affinity for 5HT1-Type Receptors | OPRK1, OPRL1, OPRD1 | CYP2C9 2221/4885HTR1A 5/4885HTR1D 6/4885 |
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GABBR1, GABRQ, GABRE | CYP2C9 1185/4885HTR1A 7/4885HTR1D 11/4885 |
| US-20100004452-A1 | 5-QUINOLINONE DERIVATIVES AS 5HT1A RECEPTOR MODULATORS FOR TREATING SEXUAL DYSFUNCTION, COGNITION IMPAIRMENT, PSYCHOTIC DISORDERS, ANXIETY, DEPRESSION, ETC. | HTR1A, HTR1D, HTR1E | CYP2C9 1277/4885HTR1A 1/4885HTR1D 2/4885 |
| US-20090312546-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | HTR1A, HTR1D, HTR1F | CYP2C9 1201/4885HTR1A 1/4885HTR1D 2/4885 |
| US-20070167423-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | HTR1A, HTR1D, HTR1F | CYP2C9 1149/4885HTR1A 1/4885HTR1D 2/4885 |
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | XDH, CYP4X1, PDHX | CYP2C9 133/4885HTR1A 47/4885HTR1D 75/4885 |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | XDH, CYP4X1, PDHX | CYP2C9 106/4885HTR1A 476/4885HTR1D 569/4885 |
| US-20060229312-A1 | Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors | HTR1A, HTR1D, HTR1F | CYP2C9 1149/4885HTR1A 1/4885HTR1D 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.